NCT03592004

Radiomics of Mp-MRI Assessing NAC Outcome in Breast Cancer

Radiomics of Multiparametric MRI for Neoadjuvant Chemotherapy Outcomes Assessment in Breast Cancer

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Chinese Academy of Sciences · Other Government
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

This is a single-arm, multicentre study that aims to assess whether Radiomics combining multiparametric MRI and clinical data could be a good predictor of the responses to neoadjuvant chemotherapy in Breast Cancer.

Detailed description

Patients undergo multiparametric MRI (including T2WI, DWI and DCE-MRI) at baseline, after 2 courses of neoadjuvant chemotherapy, and prior to the surgery at least 8 weeks after the treatment procedure. Patients undergo biopsy test in one week after the baseline MRI scan to detect the biomarkers including ER, PR, Her-2 and Ki-67, which can be used to select the treatment plan referring to the NCCN clinical guidelines. After the surgery, responses to neoadjuvant chemotherapy are determined according to the histopathologically examination of the surgically resected specimens. After completion of treatment procedure, patients are followed up for 5 years.

Conditions

• Breast Cancer
• Radiomics
• Neoadjuvant Chemotherapy
• Multi-parametric MRI

Interventions

Type	Name	Description
OTHER	neoadjuvant chemotherapy	neoadjuvant chemotherapy

Timeline

• Start date: 2018-07-18
• Primary completion: 2019-06-01
• Completion: 2022-06-01
• First posted: 2018-07-19
• Last updated: 2018-07-19

Locations

1 site across 1 country: China